Advertisement

Research Article Free access | 10.1172/JCI112756

Mechanism of activation of coagulation factor XI by factor XIIa studied with monoclonal antibodies.

H Akiyama, D Sinha, F S Seaman, E P Kirby, and P N Walsh

Find articles by Akiyama, H. in: JCI | PubMed | Google Scholar

Find articles by Sinha, D. in: JCI | PubMed | Google Scholar

Find articles by Seaman, F. in: JCI | PubMed | Google Scholar

Find articles by Kirby, E. in: JCI | PubMed | Google Scholar

Find articles by Walsh, P. in: JCI | PubMed | Google Scholar

Published December 1, 1986 - More info

Published in Volume 78, Issue 6 on December 1, 1986
J Clin Invest. 1986;78(6):1631–1637. https://doi.org/10.1172/JCI112756.
© 1986 The American Society for Clinical Investigation
Published December 1, 1986 - Version history
View PDF
Abstract

The interaction of Factor XIIa with Factor XI was investigated using two monoclonal antibodies, one (3Cl) directed against the heavy chain of Factor XIa and the other (5F4) against its light chain. 3C1 either as intact IgG or as Fab' fragment, enhanced the rate of Factor XIa generation in the fluid phase but inhibited it in the presence of kaolin and high molecular weight (HMW) kininogen. In contrast, the Fab' fragments of 5F4 inhibited only the fluid phase activation and had no effect on the surface-mediated activation. 3C1 was found to block the binding of Factor XI to HMW kininogen, whereas 5F4 did not. We conclude: a domain on the heavy chain region of Factor XI is essential for binding to HMW kininogen and for optimal surface-mediated activation by Factor XIIa; and binding of 3C1 to Factor XI changes its conformation rendering it a more favorable substrate for Factor XIIa in the fluid phase.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (December 1, 1986): No description
Advertisement
Advertisement